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Abstract
Background: The receptor for advanced glycation end products (RAGE) has been found to interact with amyloid β
(Aβ). Although RAGE does not have any kinase motifs in its cytosolic domain, the interaction between RAGE and
Aβ triggers multiple cellular signaling involved in Alzheimer’s disease (AD). However, the mechanism of signal
transduction by RAGE remains still unknown. Therefore, identifying binding proteins of RAGE may provide novel
therapeutic targets for AD.
Results: In this study, we identified p38-regulated/activated protein kinase (PRAK) as a novel RAGE interacting molecule.
To investigate the effect of Aβ on PRAK mediated RAGE signaling pathway, we treated SH-SY5Y cells with monomeric
form of Aβ. We demonstrated that Aβ significantly increased the phosphorylation of PRAK as well as the interaction
between PRAK and RAGE. We showed that knockdown of PRAK rescued mTORC1 inactivation induced by Aβ treatment
and decreased the formation of Aβ-induced autophagosome.
Conclusions: We provide evidence that PRAK plays a critical role in AD pathology as a key interactor of RAGE. Thus, our
data suggest that PRAK might be a potential therapeutic target of AD involved in RAGE-mediated cell signaling induced
by Aβ.
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Background
Alzheimer’s disease (AD), a progressive neurodegenera-
tive disorder, is the most common type of dementia [1].
Notably, Amyloid β (Aβ) is a major pathological charac-
teristic of AD [2]. Along with neurofibrillary tangles and
neuronal loss, Aβ influences AD pathogenesis, including
oxidative injury, synaptic degeneration, inflammatory
response and neuronal death. Unfortunately, the inter-
mediate mechanism underlying toxic Aβ interactions
and AD pathogenesis remains unelucidated. As a result,
current treatments can merely alleviate AD symptoms
and delay deterioration [3].
The receptor for advanced glycation end-products
(RAGE) is a multi-ligand receptor that belongs to the
immunoglobulin superfamily [4, 5]. RAGE ligands are
comprised of advanced glycation end-products [4], high
mobility group box 1 (HMGB1, also known as ampho-
terin) [6], S100/calgranulins [7, 8], Mac-1 [9], phosphati-
dylserine [10] and Aβ [11]. Interactions of ligand-RAGE
activate multiple intracellular signaling pathways involving
MAPKs such as ERK1/2, p38, JNK, PI3K, Src kinase, JAK/
STAT, TGFβ/Smad, and members of the Rho GTPase
signaling pathway [12]. Moreover, ligand-RAGE interac-
tions cause the generation of reactive oxygen species [13],
influence cellular homeostasis and inflammatory response,
and lead to diseases such as cancer, diabetes and AD [14].
Multiple lines of evidence underscore the importance
of the 42 amino acids of the RAGE cytoplasmic domain
in intracellular signal transduction. For example, dele-
tion in this RAGE cytoplasmic domain (DN-RAGE)
renders RAGE incapable of facilitating signal transduction
following ligand-RAGE interaction [15]. Furthermore, the
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absence of any known signal transduction motifs in the
RAGE cytoplasmic domain has limited our understand-
ing of AD pathogenesis through Aβ-RAGE interaction-
mediated signaling. mDia-1 is known to interact with
the RAGE cytoplasmic domain and requires RAGE-
mediated cellular migration, Rho GTPases (particularly
cdc42 and rac-1) activation for this interaction [16].
However, RAGE cytoplasmic domain binding proteins
responsible for triggering other RAGE-mediated signal-
ing pathways remain unknown.
p38-regulated/activated protein kinase (PRAK), also
known as the mitogen-activated protein kinase (MAPK)
activated protein kinase-5 (MK5), is a Ser/Thr protein
kinase and a member of the MAPKs [17]. PRAK can be
activated by cellular stress and inflammatory cytokines
[18]. PRAK is known to phosphorylate Heat shock protein
27 (HSP27) [17], cytosolic phospholipase A2 (cPLA2)
[19], tyrosine hydroxylase [20], FOXO3a [21], FAK [22],
septin8 [23] and p53 [24]. Thus, PRAK plays a crucial role
in cellular signaling phenomena such as the cell cycle,
angiogenesis, and neuronal plasticity [25]. Moreover,
PRAK regulates the phosphorylation of Ras homologue
enriched in brain (Rheb), a main component of mamma-
lian target of rapamycin complex 1 (mTORC1), leading to
decreased cell growth [26].
In this study, we found PRAK as a novel interactor of
the RAGE cytoplasmic domain using the yeast two-hybrid
approach. The interaction between PRAK and RAGE was
further verified by immunoprecipitation (IP), surface plas-
mon resonance (SPR). We identified that Aβ treatment
induced phosphorylation of PRAK and increased inter-
action between PRAK and RAGE. More interestingly, the
interaction between PRAK and RAGE was also increased
in the brains of Tg6799 mouse, AD animal model.
Furthermore, knockdown of PRAK reduced RAGE-
mediated formation of autophagosome via mTORC1
signaling pathway. Our results indicate that PRAK binds to
the RAGE cytoplasmic domain and regulates Aβ-RAGE-
mediated autophagy.
Results
Identification of PRAK as a binding partner of RAGE
To identify proteins that interact with the RAGE cyto-
plasmic domain, we carried out the yeast two-hybrid
screening between the human brain cDNA library and
RAGE cytoplasmic domain, the latter was used as the
bait. We identified interaction between PRAK and the
RAGE cytoplasmic domain through the expression of
three reporter genes, lacZ, ura3, and ade2, each being
under the control of different GAL4 promoters. To
ensure the reliability of the results, both the positive and
negative controls were incorporated on the same filter
(Fig. 1a). To validate the interaction between PRAK and
RAGE, we transfected PRAK-GFP and RAGE into cells
and performed immunoprecipitation with anti-GFP anti-
bodies (Fig. 1b). We also confirmed the interaction
between PRAK and RAGE at endogenous levels in
SH-SY5Y cells by antibodies against both PRAK and
RAGE (Additional file 1: Figure S1). We investigated
the binding kinetics between PRAK and RAGE using
surface plasmon resonance (SPR) by immobilizing
PRAK protein on the chip surface. The response unit
(RU) was gradually increased by the RAGE concentra-
tion from 2.5 μM to 40 μM (Fig. 1c). The Kd value of
the binding strength of the RAGE cytoplasmic domain to
PRAK is 0.5086 nM. This SPR data supported that the
PRAK is a specific binding protein to the RAGE cytosolic
domain.
Aβ increases PRAK-RAGE interaction
The binding of RAGE to its ligands triggers various
signaling pathways and this process is dependent on the
RAGE cytoplasmic domain. In AD, RAGE expression is
increased in the brain [11]. Aβ-RAGE interaction induces
the cellular effects associated with AD pathology [27–29].
To investigate the effect of Aβ on interaction between
PRAK and RAGE, we performed in situ proximity ligation
assay on cells overexpressing both RAGE and PRAK after
2 μM monomeric Aβ treatment. The red dots suggest
closely apposed binding of the two proteins (~40 nm). The
red dot signals increased substantially in treatment of cells
with Aβ compared to treatment of cell with vehicle (Fig. 2a).
Furthermore, to see the colocalization between PRAK and
RAGE, we used the structure illumination microscopy
(SIM) with high resolution. After treatment of monomeric
Aβ for 6 h, we stained using anti-PRAK antibody (green)
and anti-RAGE antibodies (red). Compared to vehicle
treatment, Aβ treatment increased the colocalization be-
tween PRAK and RAGE (Fig. 2b). These data indicate that
Aβ treatment increases the interaction between PRAK
and RAGE. In addition, we confirmed the interaction
between PRAK and RAGE in vivo using the brains of
Tg6799 mice as AD animal model. Consistent with
cell data using Aβ, the binding of PRAK to RAGE
was increased in the brains of Tg6799 compared to
litter mate (Fig. 2c, 19.2 % ± 1.684, * p < 0.05, n = 4
independent experiments). Taken together, these data
implicate that the interaction between PRAK and
RAGE was increased under Aβ abundant conditions in
cells as well as in vivo.
Aβ induces phosphorylation of PRAK via RAGE-intracellular
domain
Since PRAK is a protein kinase activated through phos-
phorylation in response to cellular stress and proin-
flammatory cytokine [17]. We examined whether 2 μM
monomeric Aβ treatment can induce phosphorylation
of PRAK. As expected, Aβ treatment increased the level
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of phosphorylated PRAK at Thr-142 compared to vehicle.
The mean change was about 18 % ± 3.3 (*** p < 0.001,
n = 4 independent experiments, Fig. 3a). To test
whether the RAGE cytoplasmic domain, the PRAK
binding site, is critical for phosphorylation of PRAK
after Aβ stimulation, we used cells overexpressing RAGE
or the RAGE cytoplasmic domain deletion mutant
(DN-RAGE). Full length of RAGE induced PRAK phos-
phorylation by Aβ stimulation compared with the vehicle
(19.4 % ± 4.38, ** p < 0.01, n = 3 independent experiments).
However, phosphorylation of PRAK was not altered by Aβ
treatment in cells overexpressing DN-RAGE (Fig. 3b). This
result suggests that phosphorylation of PRAK induced by
Aβ treatment is dependent on RAGE-cytoplasmic domain.
Aβ induces mTORC1 inactivation via PRAK and RAGE
mTORC1/p70S6K signaling associated with autophagy
formation is one of Aβ induced downstream signaling
pathways [29]. In addition, Rheb, the main component
of the mTORC1 complex, is a downstream substrate of
PRAK [26]. We investigated the status of Rheb and
mTORC1/p70S6K activation as a downstream signaling
pathway of Aβ induced PRAK-RAGE interaction. To see
if alteration of phosphorylation on Rheb or mTORC1/
p70S6k induced by Aβ is dependent on both PRAK and
RAGE, we used SH-SY5Y cells overexpressing DN-RAGE
or siPRAK. 2 μM monomeric Aβ treatment increased
phosphorylation of Rheb, compared with the vehicle
(13.1 % ± 2.55, ** p < 0.01, n = 4 independent experiments,
Fig. 1 PRAK interacts with the RAGE. a Yeast two-hybrid screening to identify RAGE interacting proteins in a human brain cDNA library. Yeast
transformants of the RAGE bait and human brain cDNA library were spread on selection medium SD-LWU (SD without leucine, tryptophan and
uracil), SD-LWA (SD without leucine, tryptophan and adenosine) and filter assay. pGBKT- PTB and pACT2-PTB served as the positive control (+).
pGBKT and pACT2 were used as negative control (−). b PRAK and RAGE binding in vitro. Immunoprecipitation (IP) with anti-GFP antibody was
accomplished using lysates from CHO cells transfected with RAGE and GFP-tagged PRAK, followed by western blotting with anti-RAGE antibody.
c Binding kinetics of the RAGE C-term to PRAK protein. GST-fused PRAK protein was immobilized onto a CM5 sensor chip as the ligand. The RAGE
C-term was used as the analyte from 0 to 40 μM to measure the kinetics of binding. Curves corresponding to multiple analyte concentrations
were generated to ensure the precision of the calculation of the kinetics. The binding kinetics were analyzed using BIAevaluation 3.1 software
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Fig. 4a in RAGE overexpressed cells). In contrast, Aβ
treatment did not alter phosphorylation of Rheb in cells
overexpressing DN-RAGE (n = 4 independent experi-
ments, Fig. 4a). Consistent with the results of Fig. 4a,
knockdown of PRAK using siRNA against PRAK did not
significantly increase phosphorylation of Rheb even in the
presence of Aβ (in the case of control si-RNA treated
group: 19.8 % ±9.06 increase in Aβ treated cells compared
to vehicle treated cells, ** p < 0.01, n = 4 independent ex-
periments, Fig. 4b). Since phosphorylation of Rheb inhibits
Fig. 2 Aβ treatment increases the interaction between PRAK and RAGE. a Aβ treatment increases RAGE-PRAK binding. Overexpression of RAGE
and PRAK in SH-SY5Y cells were treated with either DMSO or monomeric Aβ 2 μM for 6 h and co-localization was detected using in situ proximity
ligation assay kit. Probes in close proximity (<40 nm) are indicated by fluorescent dot signals. Scale bars represent 20 μm. b Aβ enhances the
co-localization between RAGE and PRAK. SH-SY5Y cells was induced by a 6 h treatment of DMSO or monomeric 2 μM Aβ. Immunofluorescence
analysis using anti-PRAK (green) and anti-RAGE (red) antibodies. SIM was used for image analysis. Scale bars represent 5 μm. c PRAK and RAGE
binding in vivo. Immunoprecipitation (IP) with anti-RAGE antibody was accomplished using total brain lysates from 3 months wild-type litter mates and
Tg6799, followed by western blotting with anti-PRAK antibody. Quantification of protein level was performed by densitometric analysis. Data are
mean ± SEM. n = 4. *P< 0.05
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the mTORC1/p70S6K pathway [30], we examined the
p70s6k phosphorylation levels. Compared with vehicle
treatment, phosphorylation of p70s6k was significantly de-
creased by Aβ treatment (24.1 % ± 5.34, ** p < 0.01, n = 4
independent experiments, Fig. 4c). However, Aβ treatment
did not significantly decrease p-p70s6k in cells overex-
pressing DN-RAGE (Fig. 4c). Moreover, deletion of PRAK
by si-PRAK did not alter p-p70s6k by Aβ treatment com-
pared with vehicle treated group, while si-control cells
decreased p-p70s6k by Aβ treatment compared with
vehicle treated group (21.7 % ±2.95, ** p < 0.01, n = 4 inde-
pendent experiments, Fig. 4d). Mock-transfected cells
showed similar trends on phosphorylation of Rheb and
p70s6k as cells overexpressing RAGE due to endogenous
RAGE effects when Aβ was treated even though the
degree of phosphorylation is much less (data not shown).
Therefore, these results demonstrate that the activation of
Rheb-mTORC1/p70S6K induced by Aβ is dependent on
PRAK-RAGE interaction.
PRAK mediates RAGE-Aβ-driven autophagosome
formation
Since autophagosome formation is one of the Rheb-mTOR
downstream effects, we further examined whether PRAK
involves formation of autophagosome induced by Aβ. Since
activation of mTOR suppresses autophagy induction by
phosphorylation of serine/threonine kinases, UNC-51-like
kinase 1 (ULK1) [31], we measured phosphorylation of
mTOR and ULK1 as an early marker of autophagy induc-
tion. ULK1, a mammalian autophagy initiating kinase, plays
a critical role in the early stage of autophagy [31]. 2 μM
monomeric Aβ treatment significantly decreased the phos-
phorylation of mTOR and ULK1 compared with vehicle
(mTOR: 21.4 % ±4.96, ULK1: 17.8 % ±5.21 ** p < 0.01, n = 5
independent experiments). However, the levels of p-mTOR
and p-ULK were not changed by Aβ treatment in cells
transfected with siRNA against PRAK (Fig 5a). Because
microtubule-associated protein 1A/1B-light chain 3-II
(LC3-II) is increased during formation of autophagosome
[32] and Aβ is known to induce autophagosome formation
[33], we measured the level of LC3-II by Western blot.
2 μM monomeric Aβ treatment induced accumulation of
LC3-II, but siRNA against PRAK transfected cells reduced
accumulation of LC3-II by Aβ treatment compared to
vehicle (Fig. 5b). The accumulation of LC3-II could be due
to either formation of autophagosome or blockage of
downstream in autophagy (autophagic flux) [32]. To distin-
guish these two possibilities, we used bafilomycin A1 that
blocks fusion of autophagosome with lysosomes to make
autolysosome, resulting in accumulation of LC3-II. Bafi-
lomycin A1 with Aβ treatment increased accumulation of
LC3-II compared with only Aβ treatment (Fig. 5b, si-
control lanes). In contrast, knockdown of PRAK by siRNA
against PRAK did not induce accumulation of LC3-II level
by Bafilomycin A1 with Aβ treatment compared with only
Aβ treatment (Fig. 5b, si-PRAK lanes). Taken together, it
implies that PRAK mediated accumulation of LC3-II is due
to autophagy formation, not by blockage of autophagic flux.
To evaluate actual autophagosome formation via PRAK, we
used transmission electron microscopy (TEM) to examine
the cellular ultrastructure. As shown in Fig. 5c and d, Aβ
treatment increased the accumulation of autophagosomes
(red arrows), compared with vehicle. In contrast, deletion
of PRAK did not induce accumulation of autophagosomes
by Aβ treatment. Taken together, these results demonstrate
that the Aβ-RAGE-induced autophagosome formation is
mediated by PRAK.
Discussion
RAGE mediates diverse cellular signaling pathways trig-
gered by specific ligands [34]. In this study, we provide
evidence that alteration of Rheb-mTOR/p70S6K by
interaction of Aβ-RAGE is mediated by PRAK. Since
Aβ-RAGE interaction also leads to the activation of an
Fig. 3 Aβ treatment induces phosphorylation of PRAK via RAGE. a SH-SY5Y cells were treated with either DMSO or 2 μM monomeric Aβ for
6 h. b SH-SY5Y cells were transfected with full length RAGE and DN-RAGE and subsequently treated with either DMSO or 2 μM monomeric
Aβ for 6 h. Western blot was performed with the indicated antibodies. Quantification of protein level was performed by densitometric analysis.
Data are mean ± SEM of at least 3 independent experiments. **P < 0.01, ***P < 0.001
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NF-κB dependent signaling pathway [11], we investi-
gated if PRAK can modulate activation of NF-κB
induced by Aβ-RAGE interaction. As expected, Aβ treat-
ment increased p-IκB compared with vehicle treatment.
However, knockdown of PRAK did not change the level
of p-IκB by Aβ treatment (Additional file 2: Figure S2).
Therefore, our data support that PRAK specifically me-
diates Rheb-mTORC1/p70S6K signaling pathway among
various downstream signaling pathways of Aβ-RAGE
interaction.
Fig. 4 RAGE and PRAK mediate mTORC1 inactivation by Aβ treatment. a RAGE and DN-RAGE-overexpressing SH-SY5Y cells were treated with either DMSO
or 2 μM monomeric Aβ for 6 h. b SH-SY5Y cells were transfected with plasmids expressing RAGE and then transiently re-transfected with PRAK siRNA or
scrambled control siRNA. Cells were treated with either DMSO or 2 μM monomeric Aβ for 6 h. c RAGE and DN-RAGE-overexpressing SH-SY5Y
cells were treated with either DMSO or 2 μM monomeric Aβ for 6 h. d SH-SY5Y cells were transfected with plasmids expressing RAGE and
then transiently re-transfected with PRAK siRNA or scrambled control siRNA. Cells were treated with either DMSO or 2 μM monomeric Aβ for
6 h. Western blot was performed with the indicated antibodies. Quantification of protein level was performed by densitometric analysis. Data
are mean ± SEM of 4 separate experiments. **P < 0.01
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Although ligands of RAGE and their associated signaling
pathways are well known, there are few studies of RAGE
cytoplasmic domain-interacting proteins [28]. In this study,
we identified that PRAK as an interactor of the RAGE is
recruited and phosphorylated by Aβ treatment and interact
with RAGE cytoplasmic domain. Previous studies reported
that PRAK, a substrate for atypical and conventional
MAPKs, is phosphorylated and activated by p38 and ERK3/
4 [17, 35]. In addition, it is well known that p38 is phos-
phorylated by Aβ mediated-RAGE activation [12, 36]. To
Fig. 5 PRAK mediates Aβ-induced autophagy signaling pathway. a SH-SY5Y cells were transfected with plasmids expressing RAGE and then
transiently re-transfected with PRAK siRNA or scrambled control siRNA. After 24 h, cells were treated with either DMSO or 2 μM monomeric Aβ for 6 h.
b SH-SY5Y cells were transfected with plasmids expressing RAGE and transiently retransfected with PRAK siRNA or scrambled control siRNA. After 24 h,
cells were pretreatment with 10 nM Bafilomycin A1 for 1 h and treated with either DMSO or 2 μM monomeric Aβ for 6 h. Western blot analysis was
performed with the indicated antibodies. Quantification of protein level was performed by densitometric analysis. Data are mean ± SEM of 5 separate
experiments. **P < 0.01. c Cells were co-transfected with RAGE plasmid DNA and PRAK siRNA or scrambled control siRNA. After 24 h, cells were treated
with either DMSO or 2 μM monomeric Aβ for 6 h, fixed, and stained for TEM as described in the methods section. EM images indicate PRAK-mediated
changes in the number of autophagosomes (arrows). Quantification of autophagosomes is shown in (d). Scale bars represent 1 μm. *P < 0.05
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investigate if p38 phosphorylates PRAK by Aβ-RAGE inter-
action, we measured the level of phosphorylated p38 using
western blot. Consistent with previous studies, the inter-
action between Aβ-RAGE activates p38 (Additional file 3:
Figure S3). However, p38 is also phosphorylated by Aβ
treatment in DN-RAGE overexpressing cells. This data
suggests that PRAK might be phosphorylated by the other
MAPK, but not p38, because PRAK is not phosphorylated
by Aβ treatment in DN-RAGE overexpressing cell (Fig 3b).
Zheng et al., reported that PRAK regulates mTORC1 by
phosphorylation of Rheb. They also showed that alteration
of mTORC1 by PRAK is independent of AMP-activated
protein kinase (AMPK) and Tuberous Sclerosis Complex
2 (TSC2) [26]. Our data also suggest that interaction
between RAGE and PRAK by Aβ treatment regulate
mTORC1, leading to autophagosome formation. The
mTOR forms two catalytic distinct complexes: mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
mTORC1 and mTORC2 are regulated by different
upstream and downstream components. mTORC1 is reg-
ulated by various upstream effects, such as PI3K/Akt,
GSK-3β, AMPK, LKB1, IRS-1 and MAPK [37–41]. There
are a number of downstream components of mTORC1,
including STAT3, 4EBPs and p70S6Ks [42]. mTORC1 is
highly expressed in brain and regulates multiple signaling
pathways related with protein synthesis, autophagy, cell
growth and mitochondrial function [43]. Accumulating
evidences suggest that mTORC1 plays a critical role in
AD pathology [44, 45]. In a previous study, we demon-
strated that interaction between Aβ and RAGE induces
autophagic vacuoles via the Ca2+/calmodulin-dependent
protein kinase kinase-AMPK pathway [29]. In this study,
we focused our efforts on autophagy among several PRAK
downstream signals and found that Aβ treatment in-
creases the interaction between RAGE and PRAK, in-
ducing autophagosome formation via Rheb-mTORC1/
p70s6k. Therefore, we further provided evidence that
Aβ-RAGE-mediated autophagosome formation is regu-
lated not only by CaMKKβ-AMPK signaling through
calcium, but also by Rheb-mTORC1 signaling through
PRAK. Inhibition of mTOR can induce autophagosome
formation [46] and many autophagic vacuoles can be
seen in the brains of AD patients [33, 47]. When beclin
1, one of autophagy initiating molecules, was knocked
down in neurons and transgenic mice in AD mouse
model, less autophagosome were shown and more Aβ
depositions were examined [48, 49], suggesting autoph-
agy has a beneficial role to remove Aβ accumulation.
However, since the disruption of lysosomal function
has been reported in the brains of AD patients and animal
models [50, 51], autophagic flux, fusion between autopha-
gosome and lysosome, might be impaired, resulting in less
autolysosomes. It causes the inhibition of abnormal protein
degradation [52, 53]. Many autophagic vacuoles in the
brains of AD patients might be resulted in accumulation of
autophagosomes due to blockade of autophagic flux with
lysosomal dysfunction. Out data showed that Aβ-RAGE-
PRAK axis stimulates autophagic formation via inhibiting
mTORC1/p70s6k to make autophagosome. If the function
of lysosome is intact in the brains, Aβ-RAGE-PRAK axis-
induced autophagosomes might be beneficial. Since the
exact status of lysosomes in each stages of AD is still
unknown, the role of autophagy in AD pathogenesis is
controversial. The detailed mechanism regarding autopha-
gic flux in AD should be clarified as a further study.
Conclusions
In summary, we identified that PRAK is a novel RAGE
interactor, and mediates downstream signaling by direct
binding to the cytoplasmic domain of RAGE. Specifically,
PRAK mediates the Rheb-mTORC1/p70s6k pathway by
Aβ-RAGE interaction. Our data suggest that PRAK is a
critical regulating factor that modulates RAGE downstream
signaling and RAGE-induced AD pathology.
Methods
Yeast two-hybrid screening
Yeast two-hybrid screening was performed by Panbionet,
(http://www.panbionet.com/), with the RAGE carboxyl ter-
minal (C-terminal) region (BD, binding domain) and the
human brain cDNA domain (AD, activation domain) li-
brary. RAGE C-terminal region (361-end amino acids of
RAGE) was amplified by PCR using the following primers
pair: F primer, 5′-GGC GAA TTC ATC TTG TGG CAA
AGG CGG–3′; R primer, 5′-GGC AGA TCT TCA AGG
CCC TCC AGT ACT–3′. The RAGE bait (135 nt) was
cloned into the BamHI/EcoRI sites of the pGBKT vector,
which contain the GAL4 DNA binding domain (GAL4DB).
The AD library inserts were cloned into pACT2 vector
containing a GAL4 activation domain. These two-hybrid
plasmids were co-transformed into yeast strain PBN204,
containing 3 reporters (URA3, lacZ, and ADE2) under the
control of dissimilar GAL4 promoters. In order to confirm
the interaction, positive clones were amplified by
Escherichia coli transformation or PCR. The amplified
clones were reintroduced into yeast PBN204 strain with
the RAGE bait plasmid or with a negative control plas-
mid expressing GAL4-binding domain without the bait.
pACT2-polypyrimidine tract-binding protein (PTB) and
pGBKT-PTB served were used as positive controls for
the protein-protein interactions. pACT2 and pGBKT
served were used as the negative controls. The identity
of the interactors was determined by sequencing.
Cell culture and animals
SH-SY5Y human neuroblastoma and Chinese hamster
ovary (CHO) cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, HyClone) then added
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to 10 % FBS (HyClone), 0.1 mg/mL penicillin and
streptomycin (Sigma) at 37 °C in a 5 % CO2 incubator.
Tg6799 (B6SJL-Tg [APPSwFlLon, PSEN*M146L*L286V]
6799Vas/J, Jackson Lab, stock no. 006554) and B6SJL
wild-type (littermate) mice were used for the experiments.
All animal use was performed according to the Principles
of Laboratory Animal Care (NIH publication no. 85–23,
revised 1985) and use guidelines of Seoul National
University, Seoul, Korea.
Transfection
Approximately 100 × 103 cells were seeded in tissue
culture plates and plated at 70 % confluence after 24 h.
Cells were transfected with full-length human RAGE or
DN-RAGE or PRAK constructs by using Lipofectamine
LTX (Invitrogen) according to the manufacturer’s proto-
col. PRAK siRNA (three to five target-specific 19–25 nt
siRNAs designed to knockdown gene expression) or
scrambled cotrol siRNA (Santa Cruz Biotechnology) by
using RNAiMAX (Invitrogen) according to the manufac-
turer’s protocol.
Reagents
Aβ42 peptide (AP62-0-80; American Peptide;2 μM) was
dissolved in hexafluoroisopropanol for 4 days at room
temperature. The lyophilized peptide was then dissolved
in DMSO (Sigma) [54]. For this experiments, an mono-
meric preparation of Aβ42 peptide was utilized, that was
characterized by atomic force microscopy (AFM). Bafilo-
mycin A1 (Sigma; 10nM) was dissolved in DMSO and
pretreatment 1 h before Aβ treatment.
Immunoprecipitation
CHO cells transfected with RAGE and GFP-tagged PRAK
were washed with PBS and lysed with 1 % CHAPS buffer
(Sigma). To reduce non-specific binding, pre-clearing with
protein A/G agarose (Santa Cruz Biotechnology) was
performed for 1 h at 4 °C with gentle rotating. After
bicinchoninic acid assay, equal protein lysates were immu-
noprecipitated with anti-GFP antibodies (1 μg/mL; Santa
Cruz Biotechnology), incubated overnight at 4 °C with
gentle rotating, and added to the beads for 1 h. The sam-
ples were washed in the lysis buffer and elution protein
complex with the SDS-PAGE sample loading buffer and
analyzed by western blotting as described above. Brain tis-
sue or SH-SY5Y cells were lysed with RIPA and using
ImmunoCruz™ IP/WB Optima E System (Santa Cruz Bio-
technology) according to the manufacturer’s protocol with
anti-RAGE antibodies (1 μg/mL; Millipore).
Western blot
Cells were washed with PBS and lysed in RIPA buffer
supplemented with a proteinase and phosphatase inhibi-
tor cocktail (Sigma). For whole cell lysates, cells were
sonicated and centrifuged for 20 min at 17,950 g at 4 °C.
Cell lysates were run on SDS-PAGE gels, and then trans-
ferred to PVDF membrane. After overnight incubation
at 4 °C with the primary antibody in 3 % BSA, the signal
was enhanced using Enhanced chemiluminescence (ECL,
GE Healthcare Biosciences) followed by image analysis with
Bioimaging analyzer (LAS-3000, Fuji Film, Inc.) and
Multi-Gauge (Fuji). Primary antibodies were used
against RAGE (Millipore), LC3B, p-ULK1 (S757),
ULK1, p-mTOR (S2481), mTOR, p-p70s6k, p70s6k, p-
p38, p38, p-IkB, IkB, tubulin (Cell Signaling Technology),
PRAK, GFP (Santa Cruz Biotechnology), and actin (Sigma).
Anti-p-PRAK (T182) and anti-p-Rheb (S130) antibodies
were obtained from Jiahuai Han’s Lab (Xiamen University).
Surface plasmon resonance spectroscopy (SPR)
The sensor chip CM5 with pre-immobilized anti-GST
antibodies in one flow cell was first saturated with GST-
fused PRAK protein. To analyze the binding kinetics,
multiple concentrations of RAGE C-terminal region
were diluted in HBS-EP buffer (0.01 M HEPES, pH 7.4;
0.15 M NaCl; 3 mM EDTA; 0.005 % Surfactant P20) and
infused onto the sensor chip at a flow rate of 30 μL/min
for 180 s. The response unit (RU) was recorded in real
time by Biacore (Biacore X-100 plus, Biacore, Inc.). After
the analyte infusion was stopped, the HBS-EP buffer was
poured over the chip for 420 s at a flow rate of 30 μL/min.
In order to dissociate the bounded analytes from the immo-
bilized PRAK and for acquisition of the dissociation curves.
Injection of 1 % PBS, including the HBS-EP buffer was
performed as the vehicle control. The Biacore control soft-
ware was used to measure the changes in plot, the binding
curve, and RU. The curves obtained from the SPR experi-
ments were analyzed and the dissociation equilibrium
constant for RAGE C-terminus to immobilized PRAK was
calculated using kinetic evaluation software. The dis-
sociation constant KD (M) was derived from the equa-
tion, KD = kd/ka, where kd and ka are dissociation-and
association-rate constants, respectively.
In Situ Proximity Ligation Assay
SH-SY5Y cells were co-transfected with RAGE and
PRAK, stimulated with 2 μM of Aβ for 6 h, and stained
according to the manufacturer’s instructions (Duolink;
92008, Olink Bioscience).
Immunofluorescence assay
For immunocytochemistry, cells were fixed with 4 %
PFA for 20 min at RT. Incubation was performed with
5 % BSA in PBS containing 1 % Triton X-100 for 30 min
for blocking and permeabilization. The cells were then
incubated with primary antibodies against human RAGE
(1:200; R&D Systems) and PRAK (1:500; Santa Cruz Bio-
technology) at 4 °C overnight. Finally, the cells were
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incubated with anti-rabbit Alexa 488 and anti-goat Alexa
594 (Invitrogen) at RT for 1 h, followed by DAPI stain-
ing and rinsing. The fluorescence was visualized by a
super resolution structured illumination microscopy
(Nikon N-SIM, Nikon Instruments Inc.).
Transmission electron microscopy (TEM)
Cells were fixed with 2 % PFA in 0.1 M phosphate or
cacodylate buffer (pH 7.2) and 2.5 % glutaraldehyde in
0.1 M phosphate buffer (pH 7.2) at 4 °C for 24 h. Cells
were then embedded with epoxy resin and polymerized
at 38 °C for 12 h and then at 60 °C for 48 h. Thin
sections, cut on an ultramicrotome (MT-XL, RMC Prod-
ucts), were collected on a copper grid. Samples were
thin sectioned at 65 nm. Sections were then stained with
4 % lead citrate and saturated 4 % uranyl acetate, and
examined under an electron microscope (JEM-1400,
JEOL) at 80 kV [55]. Counting the number of autophagic
structure per sheet (n = 6), using photographs taken at
20,000x magnification.
Statistical analysis
For statistical analysis, the unpaired t-test or the One-Way/
Two-Way ANOVA was performed using Graphpad Instat
5.1 (GraphPad Software Inc.). Data in figures represent
mean ± SEM.
Additional files
Additional file 1: Figure S1. Interaction between endogenous PRAK
and RAGE. SH-SY5Y cell lysates were immunoprecipitated with RAGE
antibody or normal IgG antibody. Western blot analysis performed with
the indicated antibodies. (TIFF 308 kb)
Additional file 2: Figure S2. PRAK does not mediate NF-κB activation
through Aβ-RAGE interaction. SH-SY5Y cells were transfected with plasmids
expressing RAGE and then transiently re-transfected with PRAK siRNA or
scrambled control siRNA. After 24 h, cells were treated with DMSO or
2 μM monomeric Aβ for 30 min and western blot analysis performed
with the indicated antibodies. (TIFF 532 kb)
Additional file 3: Figure S3. RAGE-independent pathway activates p38
via Aβ. RAGE and DN-RAGE-overexpressing SH-SY5Y cells were treated
with either DMSO or 2 μM monomeric Aβ for 6 h. Western blot analysis
performed with the indicated antibodies. (TIFF 494 kb)
Abbreviations
AD: Alzheimer’s disease; Aβ: Amyloid beta; DN-RAGE: dominant negative
RAGE; GFP: green fluorescent protein; IP: immunoprecipitation;
LC3: microtubule-associated protein 1 light chain 3; mTORC1: mammalian
target of rapamycin complex 1; NF-κB: nuclear factor of kappa light
polypeptide gene enhancer in B-cells; PRAK: p38-regulated/activated protein
kinase; RAGE: receptor for advanced glycation endproducts; Rheb: ras
homologue enriched in brain; SPR: surface plasmon resonance;
TEM: transmission electron microscopy; ULK1: UNC-51-like kinase 1.
Competing interest
The authors have no potential conflicts of interest to declare.
Authors’ contributions
Y.K., C.K., S.M.S., I. M-J. conceived the study. Y.K., C.K., H.S.H. and S.H. designed the
research. Y.K., C.K. performed and analyzed experiments. H.S. performed SPR
analysis. The manuscript was written by Y.K., C.K. and I. M-J with assistance from
other authors. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Research Foundation
[2015R1A2A1A05001794, 2014M3C7A1046047, 2015M3C7A1028790 and the
Medical Research Center (2012R1A5A2A44671346)] and Protein metabolism
medical research center through Seoul National University Nobel Laureates
Invitation program for I. M-J.
Received: 24 April 2015 Accepted: 4 January 2016
References
1. Blennow K, De Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:
387–403.
2. Skaper SD. Alzheimer’s disease and amyloid: culprit or coincidence? Int Rev
Neurobiol. 2012;102:277–316.
3. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–44.
4. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and
expression of a cell surface receptor for advanced glycosylation end
products of proteins. J Biol Chem. 1992;267:14998–5004.
5. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and
characterization of two binding proteins for advanced glycosylation end
products from bovine lung which are present on the endothelial cell
surface. J Biol Chem. 1992;267:14987–97.
6. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for
advanced glycation end products (RAGE) is a cellular binding site for amphoterin.
Mediation of neurite outgrowth and co-expression of rage and amphoterin in
the developing nervous system. J Biol Chem. 1995;270:25752–61.
7. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a
novel proinflammatory axis: a central cell surface receptor for S100/
calgranulin polypeptides. Cell. 1999;97:889–901.
8. Donato R. RAGE: a single receptor for several ligands and different cellular
responses: the case of certain S100 proteins. Curr Mol Med. 2007;7:711–24.
9. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The
pattern recognition receptor (RAGE) is a counterreceptor for leukocyte
integrins: a novel pathway for inflammatory cell recruitment. J Exp Med.
2003;198:1507–15.
10. He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahasi T, et al. Receptor for
advanced glycation end products binds to phosphatidylserine and assists in
the clearance of apoptotic cells. EMBO Rep. 2011;12:358–64.
11. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta
peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685–91.
12. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker
of the inflammatory response–the evidence mounts. J Leukoc Biol. 2009;86:
505–12.
13. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL.
Activation of NADPH oxidase by AGE links oxidant stress to altered gene
expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280:E685–94.
14. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced
glycation end products and RAGE: a common thread in aging, diabetes,
neurodegeneration, and inflammation. Glycobiology. 2005;15:16R–28R.
15. Rai V, Maldonado AY, Burz DS, Reverdatto S, Yan SF, Schmidt AM, et al.
Signal transduction in receptor for advanced glycation end products
(RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to
mDia1. J Biol Chem. 2012;287:5133–44.
16. Hudson BI, Kalea AZ, Del Mar AM, Harja E, Boulanger E, D’Agati V, et al.
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required
for ligand-stimulated cellular migration through activation of Rac1 and
Cdc42. J Biol Chem. 2008;283:34457–68.
17. New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, et al. PRAK, a novel protein
kinase regulated by the p38 MAP kinase. EMBO J. 1998;17:3372–84.
18. New L, Jiang Y, Han J. Regulation of PRAK subcellular location by p38 MAP
kinases. Mol Biol Cell. 2003;14:2603–16.
19. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D,
et al. Serine 727 phosphorylation and activation of cytosolic phospholipase
A2 by MNK1-related protein kinases. J Biol Chem. 2000;275:37542–51.
Kim et al. Molecular Neurodegeneration  (2016) 11:4 Page 10 of 11
20. Toska K, Kleppe R, Armstrong CG, Morrice NA, Cohen P, Haavik J. Regulation
of tyrosine hydroxylase by stress-activated protein kinases. J Neurochem.
2002;83:775–83.
21. Kress TR, Cannell IG, Brenkman AB, Samans B, Gaestel M, Roepman P, et al.
The MK5/PRAK kinase and Myc form a negative feedback loop that is
disrupted during colorectal tumorigenesis. Mol Cell. 2011;41:445–57.
22. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell
migration and angiogenesis. Adv Drug Deliv Rev. 2011;63:610–5.
23. Shiryaev A, Kostenko S, Dumitriu G, Moens U. Septin 8 is an interaction
partner and in vitro substrate of MK5. World J Biol Chem. 2012;3:98–109.
24. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, et al. PRAK is essential for
ras-induced senescence and tumor suppression. Cell. 2007;128:295–308.
25. Moens U, Kostenko S. Structure and function of MK5/PRAK: the loner
among the mitogen-activated protein kinase-activated protein kinases. Biol
Chem. 2013;394:1115–32.
26. Zheng M, Wang YH, Wu XN, Wu SQ, Lu BJ, Dong MQ, et al. Inactivation of Rheb
by PRAK-mediated phosphorylation is essential for energy-depletion-induced
suppression of mTORC1. Nat Cell Biol. 2011;13:263–72.
27. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE
potentiates Abeta-induced perturbation of neuronal function in transgenic
mice. EMBO J. 2004;23:4096–105.
28. Ding Q, Keller JN. Evaluation of rage isoforms, ligands, and signaling in the
brain. Biochim Biophys Acta. 2005;1746:18–27.
29. Son SM, Jung ES, Shin HJ, Byun J, Mook-Jung I. Abeta-induced formation of
autophagosomes is mediated by RAGE-CaMKKbeta-AMPK signaling. Neurobiol
Aging. 2012;33:1006 e1011–1023.
30. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates
the mTOR kinase. Curr Biol. 2005;15:702–13.
31. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy
through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41.
32. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al.
Guidelines for the use and interpretation of assays for monitoring autophagy
in higher eukaryotes. Autophagy. 2008;4:151–75.
33. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci.
2007;120:4081–91.
34. Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects
by diverse mechanisms of actions. Mol Cell. 2011;31:91–7.
35. Seternes OM, Mikalsen T, Johansen B, Michaelsen E, Armstrong CG, Morrice
NA, et al. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a
novel signal transduction pathway. EMBO J. 2004;23:4780–91.
36. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, et al. Receptor for
advanced glycation end product-dependent activation of p38 mitogen-
activated protein kinase contributes to amyloid-beta-mediated cortical synaptic
dysfunction. J Neurosci. 2008;28:3521–30.
37. Bertrand FE, Spengemen JD, Shelton JG, McCubrey JA. Inhibition of PI3K,
mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage
ALL in the presence of stromal cell support. Leukemia. 2005;19:98–102.
38. Woiwode A, Johnson SA, Zhong S, Zhang C, Roeder RG, Teichmann M,
et al. PTEN represses RNA polymerase III-dependent transcription by
targeting the TFIIIB complex. Mol Cell Biol. 2008;28:4204–14.
39. Narayanan SP, Flores AI, Wang F, Macklin WB. Akt signals through the
mammalian target of rapamycin pathway to regulate CNS myelination.
J Neurosci. 2009;29:6860–70.
40. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al.
Active-site inhibitors of mTOR target rapamycin-resistant outputs of
mTORC1 and mTORC2. PLoS Biol. 2009;7, e38.
41. Cleveland-Donovan K, Maile LA, Tsiaras WG, Tchkonia T, Kirkland JL, Boney CM.
IGF-I activation of the AKT pathway is impaired in visceral but not subcutaneous
preadipocytes from obese subjects. Endocrinology. 2010;151:3752–63.
42. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory
and disease. Trends Neurosci. 2010;33:67–75.
43. Perluigi M, Di Domenico F, Butterfield DA. mTOR signaling in aging and
neurodegeneration: At the crossroad between metabolism dysfunction and
impairment of autophagy. Neurobiol Dis. 2015.
44. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, et al.
Dysregulation of the mTOR pathway mediates impairment of synaptic
plasticity in a mouse model of Alzheimer’s disease. PLoS ONE. 2010;5.
45. Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson MN, Carret-Rebillat AS,
et al. Activated mTOR and PKR kinases in lymphocytes correlate with
memory and cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn
Disord. 2006;22:320–6.
46. Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation.
J Clin Invest. 2015;125:25–32.
47. Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, et al.
Autophagic vacuoles are enriched in amyloid precursor protein-secretase
activities: implications for beta-amyloid peptide over-production and localization
in Alzheimer’s disease. Int J Biochem Cell Biol. 2004;36:2531–40.
48. Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H,
et al. Impaired autophagy and APP processing in Alzheimer’s disease: The
potential role of Beclin 1 interactome. Prog Neurobiol. 2013;106–107:33–54.
49. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, et al.
The autophagy-related protein beclin 1 shows reduced expression in early
Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin
Invest. 2008;118:2190–9.
50. Nixon RA, Yang DS. Autophagy failure in Alzheimer’s disease–locating the
primary defect. Neurobiol Dis. 2011;43:38–45.
51. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive
involvement of autophagy in Alzheimer disease: an immuno-electron
microscopy study. J Neuropathol Exp Neurol. 2005;64:113–22.
52. Nixon RA. Autophagy in neurodegenerative disease: friend, foe or turncoat?
Trends Neurosci. 2006;29:528–35.
53. Li L, Zhang X, Le W. Autophagy dysfunction in Alzheimer’s disease.
Neuro-degenerative diseases. 2010;7:265–71.
54. Dahlgren KN, Manelli AM, Stine Jr WB, Baker LK, Krafft GA, LaDu MJ.
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect
neuronal viability. J Biol Chem. 2002;277:32046–53.
55. Eskelinen EL, Schmidt CK, Neu S, Willenborg M, Fuertes G, Salvador N, et al.
Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2
double-deficient fibroblasts. Mol Biol Cell. 2004;15:3132–45.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kim et al. Molecular Neurodegeneration  (2016) 11:4 Page 11 of 11
